Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Cascone, T ^a   Morelli, M P ^a   Ciardiello, Fortunato ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

EGFR; Growth factor receptors; Non small cell lung cancer; Small molecule tyrosine kinase inhibitors

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GROWTH FACTOR RECEPTOR; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR MECHANICS; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33645810382     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj921     Document Type: Article

References (16)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 1995; 19: 183-232.
2. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr Relat Cancer 2003b; 10: 1-21.
3. Mendelsohn J. Blockade of receptors for growth factors: An anticancer therapy. Clin Cancer Res 2000; 6: 747-753.
4. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970.
5. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Nat Cancer Inst 2003; 95: 851-867.
6. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
7. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46.
8. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. J Am Med Assoc 2003; 290: 2149-58.
9. Cohen MH, Williams GA, Sridhara R et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212-1218.
10. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-784.
11. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-794.
12. Thatcher N, Chang A, Parikh P et al. ISEL: A phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens. Lung Cancer 2005; 49: S4 (Abstr no. Pr4).
13. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
14. Shepherd FA, Rodrigues PJ, Ciuleanu T et al, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
15. Herbst RS, Prager D, Hermann R et al. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004.
16. Di Maio M, Gridelli C, Normanno N et al. Tryng to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in Non-Small Cell Lung Cancer. J Cell Physiol 2005; 205: 355-363.